Evidence map›Paper›PMID 36463323›Full record

ReviewBritish journal of cancer2023

Ultrasound-targeted microbubble destruction remodels tumour microenvironment to improve immunotherapeutic effect.

Senbo Liu, Yan Zhang, Yang Liu, Wenkang Wang, Shuochen Gao, Weitang Yuan, Zhenqiang Sun, Lin Liu, Chengzeng Wang

Open access · hybridAbstract readReview
In one paragraph

Review in British journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 76 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Senbo Liu *Department of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, Henan, China.
Yan Zhang *Department of Ultrasound, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, Henan, China.
Yang Liu *Department of Radiotherapy, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, 450008, Zhengzhou, China.
Wenkang WangDepartment of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, Henan, China.
Shuochen GaoDepartment of Ultrasound, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, Henan, China.
Weitang YuanDepartment of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, Henan, China.
Zhenqiang SunDepartment of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, Henan, China. fccsunzq@zzu.edu.cn.ORCID 0000-0002-9098-7296
Lin LiuHenan Institute of Interconnected Intelligent Health Management, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, Henan, China. liulin@zzu.edu.cn.ORCID 0000-0001-8973-8738
Chengzeng WangHenan Institute of Interconnected Intelligent Health Management, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, Henan, China. czw202112@zzu.edu.cn.ORCID 0000-0002-2044-8115
First Affiliated Hospital of Zhengzhou University · CNZhengzhou University · CN

Funding

National Natural Science Foundation of China 82173055National Natural Science Foundation of China U2004112National Natural Science Foundation of China (National Science Foundation of China) 81972663
6 · The paper itself

Abstract

Cancer immunotherapy (CIT) has gained increasing attention and made promising progress in recent years, especially immune checkpoint inhibitors such as antibodies blocking programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4). However, its therapeutic efficacy is only 10-30% in solid tumours and treatment sensitivity needs to be improved. The complex tissue environment in which cancers originate is known as the tumour microenvironment (TME) and the complicated and dynamic TME is correlated with the efficacy of immunotherapy. Ultrasound-targeted microbubble destruction (UTMD) is an emerging technology that integrates diagnosis and therapy, which has garnered much traction due to non-invasive, targeted drug delivery and gene transfection characteristics. UTMD has also been studied to remodel TME and improve the efficacy of CIT. In this review, we analyse the effects of UTMD on various components of TME, including CD8

Indexed as

CD8-Positive T-LymphocytesNeoplasmsAnimalsImmunotherapyMicrobubblesTumor Microenvironment

Identifiers

PMID36463323
PMCPMC9977958
OpenAlexW4310785705

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.